EUDA Health (EUDA) shares gained nearly 5% in Thursday premarket trading after the company said it signed a letter of intent to carry out due diligence regarding a potential acquisition of Chemokine, a Singapore based biotech firm.
EUDA Health said Chemokine has agreed to an exclusivity period of at least 120 days, during which it would not hold talks with any other entity regarding an acquisition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.